Shifting From Eligibility to Optimization of Transplant in Older Adults With Hematologic Malignancies
In an article published in Blood Advances, researchers from the University of Chicago reported efforts to optimize outcomes after hematopoietic cell transplantation (HCT) in...
MRD Response Predicts Survival in Blinatumomab-Treated Patients With Relapsed/Refractory ALL
In patients with relapsed/refractory B-cell precursor acute lymphocytic leukemia (ALL) who are treated with blinatumomab, achieving minimal residual disease (MRD) was associated with improved...
Patients’ Humoral Immunity Is Preserved, With Low Rates of Viral Infections, After Anti-CD19 CAR...
The two commercially available chimeric antigen receptor (CAR) T-cell products both target cells expressing the CD19 antigen, which is present on malignant and nonmalignant...
Pretransplant Bridging With Blinatumomab Reduces MRD in Children With B-Cell Acute Lymphocytic Leukemia
In a study of children with B-cell acute lymphocytic leukemia (B-ALL) who are about to undergo allogeneic hematopoietic cell transplantation (alloHCT), bridging with blinatumomab...
Certain Non-Hodgkin Lymphoma Subtypes Carry Higher Risk of Infection-Related Solid Tumor Cancers
Various subtypes of non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL) and marginal zone lymphoma (MZL), carry a risk for second infection-related solid...
Can a Patient’s Breath Detect Post-Transplant Gastrointestinal Graft-Versus-Host Disease?
Analyzing the volatile organic compounds (VOCs) expelled in the breath can help clinicians detect and monitor gastrointestinal graft-versus-host disease (GI GVHD) in patients who...
TKIs Linked to Increased Cardiovascular and Arteriothrombotic Events in Chronic-Phase CML
In patients with chronic-phase chronic myeloid leukemia (CML), treatment with tyrosine kinase inhibitors (TKIs) has been shown to increase the risk of cardiovascular and...
Hematologic Malignancies Drive In-Hospital Death Rates
In the past 17 years, the overall rate of in-hospital deaths among patients with hematologic malignancies has decreased by 30 percent, with a corresponding...
Aggressive Imatinib Dose Escalation Shows No Improvement Over Standard Escalation in CML
For patients with newly diagnosed chronic myeloid leukemia (CML), aggressive dose escalation of imatinib failed to improve response and survival rates compared with a...
Weighing Conditioning Regimens for Patients With CML Undergoing Transplant
Conditioning with a reduced-intensity, nonmyeloablative regimen was associated with similar post-transplant survival but a lower risk of chronic graft-versus-host disease (cGVHD), compared with a...
Current Issue
January 2020 Annual Meeting Edition
This issue features highlights from the 2019 ASH Annual Meeting, reflections on physician wellness, and more.
